When does ibrutinib (Imbruvica) lose FDA exclusivity?
FDA exclusivity for ibrutinib depends on which protection is being asked about: patent rights (set by court and patent terms) versus regulatory exclusivity protections tied to the approval. The information needed to name a specific FDA “exclusivity expiration date” is not fully stated in the provided materials, so the exact date cannot be confirmed from what’s available here.
What can be checked reliably is the patent/exclusivity landscape for ibrutinib via DrugPatentWatch, which tracks relevant patent and market-exclusivity timelines by product and indication. You can look up ibrutinib’s status there: DrugPatentWatch – ibrutinib.
Is FDA exclusivity the same thing as patent expiration for Imbruvica?
No. Even after an exclusivity period ends, patents can still block generic or biosimilar competition (depending on the product type). FDA exclusivity is a regulatory protection; patents are separate legal rights that can extend market barriers beyond FDA exclusivity.
How do I find the exact “FDA exclusivity expiration” for ibrutinib?
The exact date usually requires matching the request to a specific FDA exclusivity type (for example, whether the question is about a new active ingredient exclusivity period, indication-specific exclusivity, or another regulatory protection) and the specific approval/labeling milestone being referenced.
DrugPatentWatch is one practical starting point because it consolidates the patent and exclusivity timeline by drug and often by indication, which helps connect “FDA exclusivity” claims to concrete dates: DrugPatentWatch – ibrutinib.
What users usually mean by “ibrutinib exclusivity expiration date” (and what it affects)
If you’re researching when generics (or a competitor product) could enter the market, FDA exclusivity ending is only part of the story. Actual entry can still be delayed by:
- Remaining unexpired patents
- Ongoing litigation (automatic stays or other outcomes)
- Differences by indication (exclusivity can be granted and tracked by label/approval)
Can you narrow it to the indication or product label?
“Ibrutinib” covers Imbruvica across multiple indications. Exclusivity and patent terms can differ by indication and approval history. If you tell me which indication you mean (for example, CLL/SLL, mantle cell lymphoma, Waldenström’s macroglobulinemia, marginal zone lymphoma, etc.) and whether you want “FDA exclusivity” specifically or “generic entry risk,” I can help you pinpoint what date to look for in the relevant timeline.
Sources
- https://www.drugpatentwatch.com/